Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
(NasdaqGM:NEUP), BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund […]